G1 Therapeutics Inc GTHX:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD
Last | 04/26/24 EDT
3.99quote price arrow up+0.13 (+3.37%)
Volume
437,205
52 week range
1.08 - 5.00
Loading...
  • Open3.85
  • Day High4.05
  • Day Low3.84
  • Prev Close3.86
  • 52 Week High5.00
  • 52 Week High Date02/08/24
  • 52 Week Low1.08
  • 52 Week Low Date10/09/23

Key Stats

  • Market Cap208.276M
  • Shares Out52.20M
  • 10 Day Average Volume0.56M
  • Dividend-
  • Dividend Yield-
  • Beta1.70
  • YTD % Change30.82

KEY STATS

  • Open3.85
  • Day High4.05
  • Day Low3.84
  • Prev Close3.86
  • 52 Week High5.00
  • 52 Week High Date02/08/24
  • 52 Week Low1.08
  • 52 Week Low Date10/09/23
  • Market Cap208.276M
  • Shares Out52.20M
  • 10 Day Average Volume0.56M
  • Dividend-
  • Dividend Yield-
  • Beta1.70
  • YTD % Change30.82

RATIOS/PROFITABILITY

  • EPS (TTM)-0.95
  • P/E (TTM)-4.19
  • Fwd P/E (NTM)-5.71
  • EBITDA (TTM)-39.014M
  • ROE (TTM)-92.13%
  • Revenue (TTM)82.511M
  • Gross Margin (TTM)91.28%
  • Net Margin (TTM)-58.13%
  • Debt To Equity (MRQ)145.70%

EVENTS

  • Earnings Date05/01/2024
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On G1 Therapeutics Inc

 

Profile

MORE
G1 Therapeutics, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on the development and commercialization of small molecule therapeutics for the treatment of patients with cancer. The Company's lead commercial product, COSELA (trilaciclib), is a therapy indicated to proactively help protect bone marrow (myeloprotection) from the damage of chemotherapy. Its product portfolio consists of Trilaciclib and Lerociclib, both of which are CDK4/6...
Garry Nicholson
Independent Chairman of the Board
John Bailey Jr.
President, Chief Executive Officer, Director
Terry Murdock
Chief Operating Officer
John V
Chief Financial Officer
Address
700 Park Offices Drive, Suite 200
Research Triangle Park, NC
27709
United States

Top Peers

SYMBOLLASTCHG%CHG
NKTR
Nektar Therapeutics
1.32UNCHUNCH
TSVT
2Seventy Bio Inc
4.25-0.04-0.82%
PSTX
Poseida Therapeutics Inc
2.13+0.08+3.90%
ENTA
Enanta Pharmaceuticals Inc
12.37-0.11-0.88%
RCEL
AVITA Medical Inc
8.52+0.22+2.65%